how to optimize your safety pharmacology studies

Recorded July 8, 2020 | 11:00am CDT

Learn how to optimize your safety pharmacology studies 

Safety Pharmacology studies play a vital role in helping evaluate the risk of adverse physiological effects posed by new pharmaceutical products and are a required and essential part of most IND-enabling drug safety programs. Given their importance in drug development, some Sponsors also supplement their discovery and early development research with exploratory Safety Pharmacology studies to help enable critical project decisions.  

On July 8, join Sinclair Research and CorDynamics as we team up to present “How to Optimize Your Safety Pharmacology Studies.”  

Presented by Dr. Michael R. Gralinski, this webinar will explore the critical role that safety pharmacology studies play in the drug approval process, as well as how to improve your cardiovascular, CNS, respiratory, and ion channel studies to avoid potentially catastrophic delays in your development timeline.  

In our upcoming webinar, Sinclair and CorDynamics will help you learn: 

About the Presenter: Dr. Michael R. Gralinski is Chief Executive Officer and Co-founder of CorDynamics, a cardiovascular contract research organization based in Chicago. Dr. Gralinski has extensive experience in pharmaceutical development, including product safety, toxicology and safety pharmacology. He is a Past-President of the Safety Pharmacology Society and holds a B.S. in Pharmacology and Toxicology from the University of Wisconsin-Madison and a Ph.D. in Pharmacology (Cardiovascular) from the University of Michigan. 

register today!